Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cyclophosphamide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    790 result(s) found for: Cyclophosphamide. Displaying page 5 of 40.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-001421-34 Sponsor Protocol Number: TPLL2 Start Date*: 2009-12-07
    Sponsor Name:University of Cologne, Sponsor-Quality Management
    Full Title: Phase II Trial of Combined Immunochemotherapy with Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients with Previously Treated or Untreated T-Prolymphocytic Le...
    Medical condition: Untreated patients with T-prolymphocytic leukemia (T-PLL) according to WHO criteria or pretreated patients (max. one previous treatment) with T-PLL .
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001757-16 Sponsor Protocol Number: DSMMXV Start Date*: 2016-11-17
    Sponsor Name:GWT-TUD GmbH
    Full Title: Pomalidomide, ixazomib, and dexamethasone (PId) with or without intensification by cyclophosphamide (PICd): A phase II study in relapsed or refractory multiple myeloma
    Medical condition: Relapsed/refractory multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067095 Multiple myeloma progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001641-89 Sponsor Protocol Number: PM1183-C-003-14 Start Date*: 2016-06-28
    Sponsor Name:Pharma Mar S.A.
    Full Title: Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients w...
    Medical condition: Small-Cell Lung Cancer (SCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) BE (Completed) ES (Completed) DE (Completed) GR (Completed) PT (Completed) CZ (Completed) NL (Completed) BG (Completed) GB (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003389-10 Sponsor Protocol Number: HepaVac-101 Start Date*: 2017-03-29
    Sponsor Name:Istituto Nazionale Tumori G. "Pascale"
    Full Title: A phase I/II trial of IMA970A plus CV8102 following a single pre-vaccination infusion of cyclophosphamide in patients with very early, early and intermediate stage of hepatocellular carcinoma after...
    Medical condition: Very early, early and intermediate stage hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004498-29 Sponsor Protocol Number: 20190360 Start Date*: 2022-01-13
    Sponsor Name:Amgen Inc.
    Full Title: Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor...
    Medical condition: Newly Diagnosed Philadelphia (Ph)-negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned) FI (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003633-42 Sponsor Protocol Number: RBHIPF004 Start Date*: 2013-10-18
    Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust
    Full Title: A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease
    Medical condition: A diagnosis of connective tissue disease associated interstitial lung disease, based on internationally accepted criteria, in one of the following categories: o Systemic sclerosis o Idiopathic inte...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10022611 Interstitial lung disease PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10027754 Mixed connective tissue disease PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039710 Scleroderma PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10036102 Polymyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-000125-27 Sponsor Protocol Number: EORTC-1976-STBSG-QLG-ETF Start Date*: 2022-05-31
    Sponsor Name:EORTC AISBL/IVZW
    Full Title: TOLERANCE: a 3 arm randomized study on healTh-related quality Of Life of EldeRly pAtients with advaNced soft tissue sarComa undergoing doxorubicin every three weeks or doxorubicin weekly or cycloph...
    Medical condition: Advanced/metastatic soft tissue sarcoma
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) NL (Completed) CY (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005769-42 Sponsor Protocol Number: WUM-KH-AL1 Start Date*: 2023-04-13
    Sponsor Name:Warsaw Medical University/ Warszawski Uniwersytet Medyczny
    Full Title: PHASE II, MULTICENTER STUDY TO ASSESS SAFETY AND EFFICACY OF COMBINATION OF SARGRAMOSTIM WITH D-VCD THERAPY (DARATUMUMAB, CYCLOPHOSPHAMIDE, BORTEZOMIB, DEXAMETHASONE) IN UNTREATED PATIENTS WITH LIG...
    Medical condition: LIGHT CHAIN AMYLOIDOSIS (Amyloidosis AL)
    Disease: Version SOC Term Classification Code Term Level
    24.1 10021428 - Immune system disorders 10086183 AL amyloidosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001484-23 Sponsor Protocol Number: Triple-B Start Date*: 2013-05-24
    Sponsor Name:BOOG Study Center
    Full Title: Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumaB as first-line treatment in advanced triple negative Breast cancer
    Medical condition: Metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-024380-41 Sponsor Protocol Number: SPON868-10 Start Date*: 2011-08-25
    Sponsor Name:Cardiff University
    Full Title: A pilot study to assess the effect of regulatory T-cell depletion on 5T4-containing MVA(TroVax®)vaccination in patients with inoperable metastatic colorectal cancer
    Medical condition: Inoperable metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009951 Colon cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004364-11 Sponsor Protocol Number: 69HCL15_0321 Start Date*: 2016-03-07
    Sponsor Name:Hospices Civils de Lyon
    Full Title: ENDOLA A PHASE I/II TRIAL TO ASSESS THE SAFETY AND EFFICACY OF METRONOMIC CYCLOPHOSPHAMIDE, METFORMIN AND OLAPARIB IN RECURRENT ADVANCED/METASTATIC ENDOMETRIAL CANCER PATIENTS
    Medical condition: - Patients with histologically and/or cytologically documented endometrial carcinoma (type I or type II), recurrent after platinum-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014736 Endometrial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005387-25 Sponsor Protocol Number: noprofit1616 Start Date*: 2016-05-05
    Sponsor Name:Sapienza, University of Rome
    Full Title: Phase 2a Study of an Immunotherapeutic Vaccine, DPX-Survivac, Alone or with Low dose Cyclophosphamide in Primary Glioblastoma Patients Receiving Standard of Care Therapy
    Medical condition: Glioblastoma is the most common primary brain tumour in humans with the most severe prognosis. Standard treatments consist primarily of surgery in order to debulk thetumoral mass, as well as radioc...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10045172 Tumour vaccine therapies HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005046-39 Sponsor Protocol Number: IEO S267/505 Start Date*: 2006-04-07
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: A randomized phase II study to assess the activity and tolerability of two regimens of metronomic oral chemotherapy methotrexate plus cyclophosphamide and cyclophosphamide plus capecitabine co...
    Medical condition: Locally advanced inoperable or metastatic breast carcinoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10057654 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002344-23 Sponsor Protocol Number: 2020/490 Start Date*: 2020-08-19
    Sponsor Name:CHU de Besançon
    Full Title: Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin in metastatic colorectal cancer carcinoma An open-label phase II
    Medical condition: Metastatic colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000353-39 Sponsor Protocol Number: CONFRONT Start Date*: 2018-05-02
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: The CONFRONT Phase I – II Trial: ACtivatiON oF immune RespONse in paTients with R-M Head and Neck Cancer. Multimodality immunotherapy with Avelumab, short course radiotherapy and Cyclophosphamide i...
    Medical condition: R-M Head and Neck Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034813 Pharyngeal cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055104 Pharyngeal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024266-21 Sponsor Protocol Number: IEOS582/111 Start Date*: 2011-07-29
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine and vinorelbine in metastatic breast cancer patients
    Medical condition: Metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002469-37 Sponsor Protocol Number: CA209-7FL Start Date*: 2020-01-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With Hi...
    Medical condition: Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061020 Breast cancer male PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) CZ (Completed) FR (Completed) PL (Completed) NL (Completed) BE (Completed) DK (Completed) FI (Completed) IE (Completed) ES (Ongoing) PT (Completed) GB (GB - no longer in EU/EEA) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-005669-37 Sponsor Protocol Number: 26866138-LYM-3002;Phase3 Start Date*: 2008-04-29
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomised, Open-Label, Multicentre Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone (VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, ...
    Medical condition: Patients with newly diagnosed Mantle Cell Lymphoma who are not eligible for bone marrow transplant. To determine which regimen of chemotherapy (VcR-CAP or R-CHOP) provides greater benefit in new...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) CZ (Completed) AT (Completed) IT (Completed) HU (Completed) DE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-003695-47 Sponsor Protocol Number: WO39391 Start Date*: 2018-07-24
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ADJUVANT ANTHRACYCLINE/TAXANE-BASED CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN...
    Medical condition: Triple-negative breast cancer (TNBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) PL (Prematurely Ended) CZ (Completed) ES (Temporarily Halted) HU (Prematurely Ended) DK (Completed) AT (Prematurely Ended) BE (Completed) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001647-19 Sponsor Protocol Number: 2008.1 Start Date*: 2008-05-22
    Sponsor Name:Radboud University Nijmegen Medical Center
    Full Title: Treatment with synthetic adrenocoticotropic hormone (ACTH) in patients with membranous nephropathy and high risk for renal failure. A pilot study.
    Medical condition: Membranous nephropathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 19:54:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA